Skip to content

Reducing Total Cardiovascular Risk in an Urban Community

Reducing Total Cardiovascular Risk in an Urban Community

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00241904
Acronym
COACH
Enrollment
525
Registered
2005-10-19
Start date
2006-05-31
Completion date
2010-05-31
Last updated
2017-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus, Atherosclerosis, Cerebral Arteriosclerosis, Hypertension

Brief summary

PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk.

Detailed description

BACKGROUND: The study is based on the premise that a community-based participatory research partnership model, using a team of an advanced practice nurse case manager, community health worker (CHW), and physician can be translated into urban community clinics and improve the quality of care and reduce disparities in cardiovascular health in minority and other underserved populations. Despite well-publicized guidelines on the appropriate management of cardiovascular disease (CVD) and type 2 diabetes, implementation of CVD risk-reducing practices remains poor. In spite of the known benefit of lowering low-density lipoprotein cholesterol (LDL-C) levels below 100 mg/dl in persons with existing heart disease, as many as 50 to 70 percent of eligible CVD patients are not placed on lipid-lowering therapy by their providers and from 20 to 80 percent of patients do not achieve the goals of therapy. The benefits of controlling high blood pressure (HBP) are well established, yet national rates of HBP control remain at only 31 percent despite decades of provider and patient education. In addition, it is well established that control of glycemia, hyperlipidemia, and blood pressure reduce the risk of vascular complications in people with diabetes, 75 percent of whom die from some form of heart or blood vessel disease. This randomized trial will compare the clinical effectiveness and cost effectiveness of a CI intervention with a LI intervention in African American, and white low-income patients with known excessive CVD risk. DESIGN NARRATIVE: Eligible patients with CVD or type 2 diabetes will be randomly selected from two urban federally funded community clinics and randomly assigned to receive either 1) a Cl intervention delivered by a nurse practitioner, a CHW, and the patient's physician, focusing on behavioral interventions to affect therapeutic lifestyle changes and medication adherence as well as the prescription and titration of medications or 2) a LI intervention providing feedback on CVD risk factors and guidelines to patients and their physicians. Outcomes will be measured at baseline and one and two years. It is hypothesized that a higher proportion of patients in the Cl intervention group will achieve the treatment goals for lipid, blood pressure, and diabetes management, lifestyle behaviors and utilization of antiplatelet agent, beta blocker, and angiotensin converting enzyme (ACE) inhibitor therapies and that the Cl intervention will be cost-effective. Secondary outcomes include assessment of the impact of the Cl intervention model on patients' satisfaction with care and health care utilization. The increase in the percentage of high-risk women and men who receive recommended secondary prevention therapies and achieve goal levels could potentially result in a marked decrement in annual CVD mortality and health disparities if applied within primary care settings to populations with the characteristics of the target groups for this study.

Interventions

Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise

Aspirin 81 mg q day

DRUGBeta Blocker

Oral medication

Oral medications, received 1-2 times per day

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Currently receiving medical care at Johns Hopkins University * African American or Caucasian and have diagnosed CVD, defined as a prior myocardial infarction, revascularization procedure for coronary disease, ischemic heart disease, stroke, or have diagnosed type 2 diabetes and not receiving any therapy * Have either no LDL-C in their medical record during the 12 months prior to study entry or have an LDL greater than or equal to 100 mg/dl on or off lipid lowering pharmacotherapy * Have either no blood pressure recorded in their medical record during the 12 months prior to study entry or a BP greater than 140/90 mmHg or greater than 130/80 mmHg if the participant is diabetic or has renal insufficiency * If the participant is diabetic he or she has to either have no HbA1c recorded during the 12 months prior to study entry or HbA1c of 7 percent or greater

Exclusion criteria

* A serious life-threatening noncardiac comorbidity with a life expectancy of less than 5 years * A serious physician-recorded psychiatric morbidity that would interfere with the study * Sufficient neurological impairment that would interfere with the study

Design outcomes

Primary

MeasureTime frameDescription
HbA1cMeasured at 1 yearFasting for 12 hour blood sample was measured in standardized lab
Low-density Lipoprotein CholesterolMeasured at 1 yearBlood was drawn after a 12 hour fast and low density lipoprotein cholesterol was measured in a standardized lab
Systolic Blood PressureMeasured at 1 yearBlood pressure measured with automatic blood pressure machine according to the guidelines of the American Heart Association.

Secondary

MeasureTime frameDescription
Patients' Satisfaction With Care and Health Care UtilizationMeasured at 1 yearPatient satisfaction with care and healthcare utilization was measured with the Patient Assessment for Chronic Illness Care Scale (PACIC). The scores range from 0-5, with 5 being the most satisfied

Countries

United States

Participant flow

Participants by arm

ArmCount
Comprehensive Intervention
CI intervention will receive Behavioral: Lifestyle Changes, Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercises, as well as pharmacologic agents
261
Less Intensive Intervention
LI Arm: Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians.
264
Total525

Baseline characteristics

CharacteristicLess Intensive InterventionTotalComprehensive Intervention
Age, Continuous54.7 years
STANDARD_DEVIATION 11.5
54.5 years
STANDARD_DEVIATION 11.7
54.3 years
STANDARD_DEVIATION 12
Race/Ethnicity, Customized
Black
210 Participants417 Participants207 Participants
Race/Ethnicity, Customized
White
54 Participants108 Participants54 Participants
Sex: Female, Male
Female
187 Participants374 Participants187 Participants
Sex: Female, Male
Male
77 Participants151 Participants74 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 2610 / 264
serious
Total, serious adverse events
0 / 2610 / 264

Outcome results

Primary

HbA1c

Fasting for 12 hour blood sample was measured in standardized lab

Time frame: Measured at 1 year

Population: Only the participants with a diagnosis of diabetes were assessed for this outcome measure

ArmMeasureValue (MEAN)Dispersion
Comprehensive Intervention GroupHbA1c8.3 percentage of hemoglobinStandard Deviation 2.2
Less Intensive Intervention GroupHbA1c8.2 percentage of hemoglobinStandard Deviation 2.1
p-value: 0.034General Linear Mixed Model
Primary

Low-density Lipoprotein Cholesterol

Blood was drawn after a 12 hour fast and low density lipoprotein cholesterol was measured in a standardized lab

Time frame: Measured at 1 year

ArmMeasureValue (MEAN)Dispersion
Comprehensive Intervention GroupLow-density Lipoprotein Cholesterol100.1 mg/dLStandard Deviation 39.2
Less Intensive Intervention GroupLow-density Lipoprotein Cholesterol110.6 mg/dLStandard Deviation 36.8
Comparison: Intention to treat analysis was usedp-value: <0.001General Linear Mixed Model
Primary

Systolic Blood Pressure

Blood pressure measured with automatic blood pressure machine according to the guidelines of the American Heart Association.

Time frame: Measured at 1 year

ArmMeasureValue (MEAN)Dispersion
Comprehensive Intervention GroupSystolic Blood Pressure130.8 mmHgStandard Deviation 20.7
Less Intensive Intervention GroupSystolic Blood Pressure135.9 mmHgStandard Deviation 20.5
p-value: 0.003General Linear Mixed Model
Secondary

Patients' Satisfaction With Care and Health Care Utilization

Patient satisfaction with care and healthcare utilization was measured with the Patient Assessment for Chronic Illness Care Scale (PACIC). The scores range from 0-5, with 5 being the most satisfied

Time frame: Measured at 1 year

ArmMeasureValue (MEAN)Dispersion
Comprehensive Intervention GroupPatients' Satisfaction With Care and Health Care Utilization2.9 units on a scaleStandard Deviation 0.9
Less Intensive Intervention GroupPatients' Satisfaction With Care and Health Care Utilization1.8 units on a scaleStandard Deviation 1
p-value: <0.001General Linear Mixed Model

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026